• Iroko Pharmaceuticals LLC, of Philadelphia, reported Phase III study results that showed patients treated with its submicron particle, lower-dose diclofenac experienced significant pain relief following surgery compared with placebo. Read More
• Teva Pharmaceutical Industries Ltd., of Jerusalem, launched its generic equivalent of Symbyax (olanzapine and fluoxetine, Eli Lilly and Co.) in the U.S. Read More
• Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., said it received a Nasdaq letter indicating the firm is not in compliance with the minimum bid price requirement for continued listing. Catalyst has 180 calendar days to regain compliance. Read More
• Glythera Ltd., of Newcastle, UK, secured a fund-raising round with IP Group totaling $3.1 million, which will be tranched over three years. Read More
Panelists in one session at the BIO International Convention in Boston were discussing why so many drug development companies were chasing too few targets. Read More
WASHINGTON – Drug researchers counting on National Institutes of Health (NIH) support could be in for a bit of a drought next year, as a federal budget sequester, set to go into effect Jan. 1, 2013, would dry up funding for about 2,300 grants – one-fourth of the grants the NIH typically awards. Read More
The American Association for the Advancement of Science published full details of a paper by Dutch researchers that demonstrates H5N1 avian influenza, a highly lethal but to date not very contagious strain of the flu, can acquire mutations that allow it to be spread via aerosol transmission. Read More
BOSTON – The wave of consolidation that has swept through the pharmaceutical sector has reduced the number of potential buyers for a biotech at the same time as a closed initial public offering (IPO) window has made mergers and acquisitions (M&A) the only possible exit. Read More
BOSTON – Is it practical to still designate China – a market that is closing in on Japan as the world's second-largest pharma market – as a potential market? Or regard Russia's biopharma industry status as an emerging one, when its clinical trials infrastructure is rated in the global top five by the FDA? Read More
• Medigene AG, of Martinsried, Germany, said that a clinical formulation trial with RhuDex achieved positive results and that the further clinical development of the drug for the treatment of autoimmune diseases will continue with an optimized oral formulation. Read More
